Markets:

Overview

News

Currencies

International

Treasuries

Bausch Health Companies Inc. Common Stock (NY:BHC)

6.820 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Opening Day: Tenon Medical Shares Soar In Market Debut ↗

April 30, 2022

Shares of Tenon Medical soared in their market debut on Wednesday, opening at $22.05 after the medical-device company had priced its IPO at $5 per share. Meanwhile, Belite Bio opened on April 29 at...

Via Talk Markets

Jim Cramer Says This Stock Is Still Terrific ↗

April 25, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tredegar Corporation (NYSE: TG) was terrific at the time it became public, and it is terrific now also.

Via Benzinga

IPO Market Stalls With Potential Blockbuster Deals Waiting For Rebound ↗

April 07, 2022

Though IPOs in the first quarter plunged to their lowest level in six years, many companies are in the pipeline ready to go public.

Via Investor's Business Daily

Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO ↗

March 26, 2022

Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...

Via Talk Markets

Opening Day: Cannabis Name Akanda Opens Way Above IPO Pricing, Pulls Back ↗

March 19, 2022

On its first trading day, Akanda fell about 65% from its opening price of $30, though that opening price was nearly eight-times its IPO price of $4. Meanwhile, startup Knock scrapped its plans to go...

Via Talk Markets

Opening Day: New Stock Offerings Slump To Lowest Number In A Decade ↗

March 05, 2022

It was another slow week for IPOs in the U.S. New stock offerings slumped to the lowest number in over a decade last month amid the war in Ukraine and as rising borrowing costs sent share prices...

Via Talk Markets

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View ↗

February 23, 2022

Bausch Health Companies Inc (NYSE: BHC) has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion. Excluding the impact of foreign...

Via Benzinga

Bausch Health Companies: Q4 Earnings Insights ↗

February 23, 2022

Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Recap: Bausch Health Companies Q4 Earnings ↗

February 23, 2022

Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

Preview: Bausch Health Companies's Earnings ↗

February 22, 2022

Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Opening Day: Nutraceutical Seller Smart For Life Plunges Following IPO ↗

February 19, 2022

Shares of Smart for Life plunged about 75% following its initial public offering on the Nasdaq. Blue Water Vaccines opened at $50 after having priced its initial public offering of 2.22 million shares...

Via Talk Markets

Why The Justice Department Is Going After Short Sellers ↗

February 17, 2022

Federal prosecutors are reportedly ramping up a probe into the activities of short sellers, serving subpoenas and seizing hard drives and mobile phones of prominent "activist...

Via Benzinga

Two Insider Moonshots Rising on Sudden Buying ↗

February 10, 2022

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Via InvestorPlace

Jim Cramer Buys The Dip In Salesforce, Marvell And This Health Stock ↗

January 21, 2022

With the markets falling further into correction territory, Jim Cramer decided to start adding to some of the positions in hi...

Via Benzinga

Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO ↗

January 14, 2022

Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would...

Via Benzinga

The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake ↗

January 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...

Via Benzinga

Jim Cramer's Top Stocks For 2022: Eli Lilly, Honeywell And More ↗

January 05, 2022

Jim Cramer announced his top stock picks for 2022 Wednesday on CNBC's "Fast Money Halftime Report." The fo...

Via Benzinga

Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions ↗

December 29, 2021

December is when analysts and banks issue their extensive stock market outlook and winning stocks for the new year.

Via InvestorPlace

BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health ↗

December 20, 2021

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

Via InvestorPlace

4 Stocks Insiders Are Buying ↗

December 03, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Why Did Bausch Health Shares Plunge Today? ↗

November 02, 2021

Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign...

Via Benzinga

Bausch Health Companies inc (BHC) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

BHC earnings call for the period ending October 2, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO ↗

October 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

Friday Market Coverage ↗

October 08, 2021

New hiring again failed to rise in Sept., the 2nd month in a row which may be good news because it could delay the Fed tapering.

Via Talk Markets

Topics Economy

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Why Bausch Health Companies Stock Zoomed 8% Higher Today ↗

September 21, 2021

One analyst crunches the numbers to come up with a share price valuation well above current levels.

Via The Motley Fool

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bausch Health Companies Inc. Common Stock (NY:BHC)

All News about Bausch Health Companies Inc. Common Stock

Starting at $3.75/week.

Subscribe Today